Perrigo in patent settlement with Cadence over Ofirmev

Cadence Pharmaceuticals (Nasdaq: CADX) has entered into settlement and license agreements with fellow USA-based Perrigo (Nasdaq: PRGO), and its subsidiary, Paddock Laboratories, to resolve pending patent litigation involving Ofirmev (acetaminophen) injection, a drug used for the management of mild-to-moderate pain.

The accord includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence in the US District Court for the District of Delaware relating to the Abbreviated New Drug Application, filed by Paddock with the US Food and Drug Administration for a generic version of Ofirmev injection. Litigation remains ongoing against Exela Pharma Sciences, Exela PharmaSci, Inc. and Exela Holdings, said Cadence.

Gets first refusal rights for authorized generic